- 25-Apr-2025
- Healthcare and Medical Malpractice
In India, medical research involving human subjects must undergo rigorous ethical review and approval processes to ensure participant safety and uphold ethical standards. The primary bodies responsible for authorizing such research are Institutional Ethics Committees (IEC), the Drugs Controller General of India (DCGI), and the Indian Council of Medical Research (ICMR).
The Institutional Ethics Committee (IEC), also known as the Institutional Review Board (IRB) in some places, is the primary body responsible for reviewing and approving medical research proposals involving human subjects.
The IEC ensures that the research follows ethical guidelines, protects the rights and safety of participants, and guarantees that informed consent is obtained.
Before starting any clinical trial or research, researchers must submit their proposal to the IEC for approval. The committee evaluates the research protocol, risks to participants, benefits, informed consent procedures, and ensures the study complies with ethical standards.
The Drugs Controller General of India (DCGI), under the Central Drugs Standard Control Organization (CDSCO), is the regulatory authority that approves the clinical trials and research involving drugs and medical devices.
The DCGI’s approval is mandatory before conducting clinical trials on humans, particularly when a new drug, vaccine, or medical device is being tested.
The DCGI ensures that clinical trials are conducted in accordance with the Drugs and Cosmetics Act, 1940, and the Clinical Trials Rules, 2019. The DCGI is responsible for reviewing the trial protocol, ensuring safety measures are in place, and confirming that the trial will not put participants at undue risk.
The Indian Council of Medical Research (ICMR) is the apex body in India responsible for formulating guidelines and policies for medical research involving human subjects.
While ICMR does not directly approve individual research projects, it provides the ethical framework and guidelines that must be followed. The ICMR Ethical Guidelines for Biomedical Research on Human Participants outlines the requirements for obtaining informed consent, the roles of Institutional Ethics Committees (IEC), and the process of clinical trial registration.
The ICMR collaborates with the DCGI and other institutions to ensure that medical research complies with national and international ethical standards.
The Central Drugs Standard Control Organization (CDSCO) is the national regulatory authority under the Ministry of Health and Family Welfare responsible for regulating drugs and clinical trials in India.
In addition to the DCGI, the CDSCO provides oversight of the approval process for clinical trials, including those involving human subjects, ensuring that they comply with regulations related to drug safety, adverse events, and other public health considerations.
Researchers must submit a detailed research proposal to the Institutional Ethics Committee (IEC). The proposal should include the study objectives, methodology, participant inclusion and exclusion criteria, risk assessment, and plans for obtaining informed consent.
If the study involves new drugs or medical devices, the proposal should also be submitted to the Drugs Controller General of India (DCGI) for regulatory approval.
The IEC evaluates how informed consent will be obtained from participants. This ensures that all participants are fully aware of the nature of the study, potential risks, benefits, and their right to withdraw at any time without consequences.
The ICMR guidelines stress the importance of obtaining voluntary, written, and informed consent from all human participants before they participate in the study.
The IEC reviews the study from an ethical standpoint, ensuring that the risks to human subjects are minimized and that the research complies with national and international ethical standards, such as those outlined in the Declaration of Helsinki.
Ethical considerations include privacy protection, confidentiality, risk-benefit analysis, and ensuring that vulnerable populations (e.g., children, pregnant women) are adequately protected.
After obtaining IEC approval, the research proposal must be submitted to the Drugs Controller General of India (DCGI) if it involves investigational drugs, vaccines, or medical devices.
The DCGI reviews the application to ensure the safety and efficacy of the drugs or devices being tested and grants permission to conduct the clinical trial on human subjects.
Once the research begins, continuous monitoring by the IEC and DCGI ensures that the study adheres to ethical standards, regulatory requirements, and that the participants' rights and safety are upheld.
Regular progress reports must be submitted to both the IEC and DCGI, especially in case of any adverse events or deviations from the study protocol.
A pharmaceutical company planning a clinical trial of a new drug must:
Medical research on human subjects in India requires authorization from multiple authorities, primarily the Institutional Ethics Committees (IEC), the Drugs Controller General of India (DCGI), and adherence to ICMR guidelines. The approval process ensures that research is conducted ethically, prioritizing participant safety, informed consent, and compliance with regulatory frameworks. By following these rigorous protocols, the safety of research participants is protected, and the integrity of scientific findings is maintained.
Answer By Law4u Team
Discover clear and detailed answers to common questions about Healthcare and Medical Malpractice. Learn about procedures and more in straightforward language.
